Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed acquisition of PotlatchDeltic by Rayonier, which involves a stock exchange offer for shareholders [1] Group 1: Acquisition Details - PotlatchDeltic shareholders will receive 1.7339 shares of Rayonier common stock for each share of PotlatchDeltic they hold [1] - Following the acquisition, PotlatchDeltic stockholders will own approximately 46% of the combined company [1] - The transaction is anticipated to close in early 2026 [1] Group 2: Legal Investigation - Rowley Law PLLC is representing shareholders in investigating the acquisition for potential securities law violations [1] - Additional information regarding the investigation can be obtained through Rowley Law PLLC's website or by contacting their office directly [2]

Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm Point Bonita Capital are under investigation for potential violations of federal securities laws following their significant exposure to the bankrupt First Brands Group, LLC [1][2][4]. Group 1: Company Overview - Jefferies is an investment banking and capital markets firm, while Point Bonita Capital serves as its trade finance division [2]. - Both firms were closely associated with First Brands Group, an auto parts supplier that declared bankruptcy in September 2025 [2]. Group 2: Financial Exposure - On October 8, 2025, Jefferies disclosed that it and Point Bonita had approximately $715 million in exposure to First Brands' receivables, which constitutes about 25% of Point Bonita's trade finance portfolio [3]. - Following this announcement, Jefferies' stock price dropped by $4.66, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [3]. Group 3: Legal Investigation - Bleichmar Fonti & Auld LLP is investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors regarding their exposure to First Brands [4].

Core Viewpoint - Quantum BioPharma Ltd. strongly refutes allegations of securities law violations made by The Schall Law Firm and DJS Law Group, describing the claims as vague and unsubstantiated [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [5]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [5]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is linked to its product unbuzzd™, and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5]. Legal Response - The company views the announcements from the law firms as opportunistic litigation tactics aimed at exploiting public markets without merit [3]. - Quantum BioPharma is reviewing the conduct of the law firms involved and plans to take appropriate action to protect its reputation [3]. Call for Information - The company invites individuals or entities who feel they have been treated unfairly by the law firms to come forward, assuring confidentiality [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Snap Inc. regarding a potential class action lawsuit due to misleading statements about the company's advertising revenue growth, which significantly declined during the reported period [1][3]. Summary by Sections Allegations - The complaint alleges that Snap Inc. provided overly positive statements to investors while concealing material adverse facts about its advertising revenue growth rate, which fell from 9% in Q1 to only 1% in April 2025 [3]. Financial Impact - On August 5, 2025, Snap announced a deceleration in advertising revenue growth, attributing it to issues with its ad platform and other factors. Following this announcement, Snap's stock price dropped from $9.39 to $7.78 per share, a decline of approximately 17.15% in one day [3]. Class Action Details - The class period for the lawsuit is from April 29, 2025, to August 5, 2025. Shareholders are encouraged to register for the class action by October 20, 2025, to participate in potential recovery [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to false or misleading statements by companies, emphasizing the importance of responsible business practices [5].

Core Viewpoint - V.F. Corporation (VFC) is facing a class action lawsuit due to allegations of disseminating false and misleading statements regarding its turnaround plans for the Vans brand, which has resulted in significant revenue setbacks [1][2]. Summary by Sections Allegations - The complaint claims that VFC concealed material adverse facts about its turnaround plans, specifically that additional significant reset actions were necessary for Vans to return to growth [1]. - The company's fourth quarter and full-year fiscal 2025 results revealed a decline in Vans' growth trajectory, with losses worsening from an 8% decline in the previous quarter to a 20% loss in the fourth quarter [1]. - VFC attributed its disappointing results to "deliberately reduced revenue" aimed at eliminating unprofitable businesses and noted that even without these actions, Vans would have experienced a "high single digit" revenue decline [1]. Stock Price Impact - Following the disclosure of the negative results, VFC's stock price dropped from $14.43 per share on May 20, 2025, to $12.15 per share on May 21, 2025, marking a decline of approximately 15.8% in one day [1]. Next Steps for Shareholders - Shareholders who purchased VFC shares during the specified class period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for November 12, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2].

Core Viewpoint - The Schall Law Firm is investigating Informatica Inc. for potential violations of securities laws following a significant drop in its stock price after disappointing financial results [1][2]. Group 1: Investigation Details - The investigation is centered on whether Informatica made false or misleading statements or failed to disclose important information to investors [2]. - Informatica reported its Q4 2024 and full year 2024 financial results on February 13, 2025, missing financial projections [2]. - The company experienced a year-over-year decrease in GAAP total revenues, subscription revenues, and the midpoint of non-GAAP operating income [2]. Group 2: Market Reaction - Following the release of the financial results, Informatica's shares fell by more than 21% [2].

Core Insights - MoonLake Immunotherapeutics is under investigation by Block & Leviton for potential securities law violations following a significant drop in share price after disappointing Phase 3 trial results [2][4]. Company Performance - Shares of MoonLake Immunotherapeutics fell over 85% in pre-market trading on September 29 due to the failure of one Phase 3 trial to meet its primary endpoint and modest gains in another trial compared to placebo [2]. - The Phase 3 data is considered to fall short of the previously touted Phase 2 MIRA trial results and is lagging behind competing drugs, raising concerns about the drug's commercial viability [2]. Legal Actions - Block & Leviton is investigating the public statements made by MoonLake regarding its drug trials and may file an action to recover losses for investors [4]. - Investors who have lost money on their MoonLake investments are encouraged to contact Block & Leviton for potential recovery options [5]. Investor Eligibility - Any individual who purchased common stock of MoonLake Immunotherapeutics and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Whistleblower Information - Individuals with non-public information about MoonLake are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. CarMax reported disappointing financial results for Q2 2025 on September 25, 2025. The Company reported a 6.3% drop in comparable store used unit sales, and a decline in net earnings for the quarter. CarMax shares fell roughly 20% in response to its disappointing results. Accessibility StatementSkip Navigation If you are a shareholder who suffered ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements about the company's drug application process for MOLBREEVI BLA [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [3]. - Specific allegations include a lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [3]. - The delay in regulatory approval raised concerns that Savara would need to raise additional capital, contradicting the company's public statements [3]. Group 2: Class Action Details - Shareholders who purchased shares of SVRA during the specified class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Insights - MoonLake Immunotherapeutics' shares dropped over 85% in pre-market trading on September 29 due to disappointing Phase 3 VELA trial results, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [2] - The Phase 3 data is considered inadequate compared to the previously reported Phase 2 MIRA trial results and is lagging behind competing drugs, raising concerns about the drug's commercial viability [2] - Block & Leviton is investigating potential securities law violations related to MoonLake's public statements about its drug trials [4] Company Overview - MoonLake Immunotherapeutics is a company involved in drug development, specifically in immunotherapeutics [2] - The company had previously highlighted positive results from its Phase 2 MIRA trial, which are now being overshadowed by the Phase 3 results [2] Legal Investigation - Block & Leviton is actively investigating whether MoonLake Immunotherapeutics committed securities law violations and may file actions to recover losses for affected investors [4] - Investors who have lost money on their MoonLake investments are encouraged to contact Block & Leviton for potential recovery options [5] Investor Eligibility - Any investor who purchased common stock of MoonLake Immunotherapeutics and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their shares [3] Whistleblower Information - Individuals with non-public information about MoonLake Immunotherapeutics are encouraged to assist in the investigation or report to the Securities Exchange Commission under the whistleblower program, with potential rewards for original information [6]